C(OC(=O)[N:7]=[C:8]1[N:12]([CH2:13][C:14]2[CH:19]=[CH:18][CH:17]=[C:16]([Br:20])[CH:15]=2)[C:11]2[CH:21]=[CH:22][CH:23]=[CH:24][C:10]=2[N:9]1[CH2:25][CH2:26][CH2:27][O:28][C:29]1[CH:34]=[CH:33][CH:32]=[C:31]([C:35]([NH:37][S:38]([CH3:41])(=[O:40])=[O:39])=[O:36])[CH:30]=1)(C)(C)C.Cl>CO>[Br:20][C:16]1[CH:15]=[C:14]([CH:19]=[CH:18][CH:17]=1)[CH2:13][N:12]1[C:11]2[CH:21]=[CH:22][CH:23]=[CH:24][C:10]=2[N:9]([CH2:25][CH2:26][CH2:27][O:28][C:29]2[CH:30]=[C:31]([CH:32]=[CH:33][CH:34]=2)[C:35]([NH:37][S:38]([CH3:41])(=[O:40])=[O:39])=[O:36])[C:8]1=[NH:7]To [1-(3-bromo-benzyl)-3-[3-(3-methanesulfonylaminocarbonyl-phenoxy)-propyl]-1,3-dihydro-benzoimidazol-ylidene]-carbamic acid tert-butyl ester (90 mg, 0.14 mmol) at rt was added HCl in MeOH (5 ml). The reaction was stirred until the consumption of the starting material was observed by TLC. After this time, the mixture was concentrated under reduced pressure and purified by chromatography on basic alumina eluting with 10% MeOH/chloroform to provide N-(3-{3-[3-(3-bromo-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-propoxy}-benzoyl)-methanesulfonamide (27 mg, 35%). HPLC-MS 557, 559 [M+1]+.
Loading…